多肽、蛋白类药物脂质体研究进展  

The Development of Liposomes of Polypeptide and Protein Drugs

作　　者：张宏波[1] 项琪[2] 赵文[3] 黄亚东[1] 李校堃[2] 

机构地区：[1]暨南大学医药生物技术研究开发中心 [2]暨南大学基因工程药物国家工程研究中心 [3]暨南大学药学院,广州510632

出　　处：《中国生物工程杂志》2007年第6期101-106,共6页China Biotechnology

基　　金：广东省科技攻关计划(2004A10902006)(2004B10410109)资助项目

摘　　要：脂质体做为多肽、蛋白类药物一种新型给药载体有控制药物释放、降低药物的毒性、提高药物的靶向性等突出优点,具有广阔的应用前景。通过查阅近10年来多肽和蛋白类药物脂质体研究的相关资料,总结论述了脂质体作为多肽、蛋白类药物载体在新的制备方法、新型脂质体、产业化进展三个方面的最新研究动向,指出了多肽、蛋白类药物脂质体在研究应用中存在的不足,并展望了多肽、蛋白类药物脂质体未来发展方向。Liposomes are artificial membrane vesicles which can be used as either passive or active targeted drug carrier systems. In polypeptide and protein drug-delivery systems, liposomes have some unique therapeutic advantages, such as the ability to deliver drugs to specific sites, to protect polypeptide and protein from degradation in the digestion track , and to increase the systemic circulation time of the drug when PEGylated liposomes are used. In this article, the latest developments including the novel methods of liposomal preparation, new forms of liposomes and the progress in industrialized production of liposomes, are summarized. In addition, some problems existing in this drug-delivery system are put forward and some possible developments of polypeptide and protein liposomes in the future is prospected. Although liposomes have been made much progress in biological area, there still exist many tough problems having not been settled.

关 键 词：多肽 蛋白质 药物 脂质体 

分 类 号：Q516[生物学—生物化学]